Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Vision-Specific Quality of Life in Patients with Post-Acute Sequelae of COVID-19 (PASC)
Neuro-ophthalmology/Neuro-otology
P18 - Poster Session 18 (5:30 PM-6:30 PM)
2-005
Infection with SARS-CoV-2 (COVID-19) involves multiple systems, including those for vision.   People with post-acute sequelae of COVID-19 (PASC) have reported many neurological symptoms such as brain fog, memory difficulties, and headache, as well as vision related complaints.  

We sought to describe post-acute symptoms of COVID-19 (PASC)-related visual symptoms in a cohort of non-hospitalized individuals presenting to our outpatient neurology practices and undergoing vision-specific quality of life assessments.

Participants completed standardized and well-validated vision-specific quality of life questionnaires, including the 25-Item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) and the 10-Item Neuro-Ophthalmic Supplement to the NEI-VFQ-25 (NOS).  Patient scores were compared to those of disease-free controls within the same age groups.  

Among 50 participants reporting persistent COVID-related symptoms more than 6 weeks after acute illness, the average age was 49.3 ± 14.6 years; 33/50 (65%) were female.  Symptoms reported by patients were mostly general and not  visual.  However, vision-specific quality of life scores were significantly lower than values for normal healthy controls with no history of neurological or ophthalmological disease (p<0.0001 for both the NEI-VFQ-25 and NOS composite scores, two-sample t-tests).  Mean NEI-VFQ-25 composite score was 89.5 ± 12.7 compared to 98.2 ± 2.1 for healthy controls.  Mean NOS score was 82.7 ±  16.0 compared to 96.5 ± 5.2 for controls.

People with post-acute sequelae of COVID-19  (PASC) in a neurology outpatient practice, even among those without visual symptoms that bring them to medical attention, report persistent visual  quality of life impairment.  These data support the inclusion of vision-specific outcome measures and symptom scales in studies of PASC, and confirm that COVID-19 infection may impair visual function.  

Authors/Disclosures
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine)
PRESENTER
An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia. Dr. Balcer has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for North American Neuro-Ophthalmology Society.
No disclosure on file
Lisena Hasanaj (NYU Langone Medical Center) Ms. Hasanaj has nothing to disclose.
No disclosure on file
Steven Galetta, MD, FAAN (NYU Langone Medical Center) Dr. Galetta has nothing to disclose.
Sujata P. Thawani, MD (NYU Neurology Associates) Dr. Thawani has nothing to disclose.